Fumapharm (Royalty interest in BG-12 and Fumaderm) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Fumapharm (Royalty interest in BG-12 and Fumaderm) General Information
Description
A portfolio of royalty interests in therapeutic medicines. The portfolio comprises of BG-12, an oral therapeutic medicine for the treatment of relapsing-remitting multiple sclerosis and Fumaderm, a therapeutic medicine for the treatment of moderate to severe plaque psoriasis.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
- Haldenstr. 24a
- 6006 Lucerne
- Switzerland
Fumapharm (Royalty interest in BG-12 and Fumaderm) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Fumapharm (Royalty interest in BG-12 and Fumaderm) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|